Azerbaijani
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Safety of Fresolimumab in the Treatment of Osteogenesis Imperfecta

Yalnız qeydiyyatdan keçmiş istifadəçilər məqalələri tərcümə edə bilərlər
Giriş / Qeydiyyatdan keçin
Bağlantı panoya saxlanılır
Statusİşə qəbul
Sponsorlar
Baylor College of Medicine
Əməkdaşlar
Genzyme, a Sanofi Company
Shriners Hospitals for Children
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Hospital for Special Surgery, New York
University of California, Los Angeles
University of Nebraska
Oregon Health and Science University
University of South Florida

Açar sözlər

Mücərrəd

Osteogenesis Imperfecta (OI) is a rare disorder that causes bones to break easily. People with OI may have broken bones with little or no trauma, dentinogenesis imperfecta (DI), and, in adult years, hearing loss. OI can range from very severe to very mild. The current standard-of-care for severe types of OI involves the use of IV medications (bisphosphonates) and surgery to put rods in bones to strengthen them. These therapies, although often life-saving, are new and very little is known about their long-term effects on bone and other body systems.
Transforming growth factor beta (TGF-β) is a protein important in bone formation. Fresolimumab is an antibody that can silence TGF-β . In studies with mice with OI, it has been shown that silencing TGF-β can lead to higher bone mass, quality and strength. The purpose of this study is to determine if fresolimumab is safe in the treatment of OI.

Təsvir

Osteogenesis Imperfecta (OI) is a rare disorder that causes bones to break easily. People with OI may have broken bones with little or no trauma, dentinogenesis imperfecta (DI), and, in adult years, hearing loss. It is seen in both genders and all races. OI can range from very severe to very mild. Individuals with the most severe type of OI may die at birth. People with severe OI who survive may have bowed arms and legs, very short stature and be unable to walk. People with the mildest form of OI may only break bones occasionally and have normal height and lifespan. Breaks can occur in any bone, but are most common in the arms and legs. The current standard-of-care for severe types of OI involves the use of IV medications (bisphosphonates) and surgery to put rods in bones to strengthen them. These therapies, although often life-saving, are new and very little is known about their long-term effects on bone and other body systems.

TGF-β is a protein important in bone formation. Studies have shown that increased TGF-β activity leads to lower bone mass and strength and increased fractures. Fresolimumab is an antibody that can silence TGF-β . In studies with mice with OI, it has been shown that silencing TGF-β can lead to higher bone mass, quality and strength.

Tarixlər

Son Doğrulandı: 03/31/2020
İlk təqdim: 10/12/2016
Təxmini qeydiyyat təqdim edildi: 02/20/2017
İlk Göndərmə: 02/23/2017
Son Yeniləmə Göndərildi: 04/06/2020
Son Yeniləmə Göndərildi: 04/07/2020
Həqiqi Təhsilin Başlama Tarixi: 11/14/2017
Təxmini İlkin Tamamlanma Tarixi: 07/31/2022
Təxmini İşin Tamamlanma Tarixi: 09/30/2022

Vəziyyət və ya xəstəlik

Osteogenesis Imperfecta

Müdaxilə / müalicə

Drug: Fresolimumab

Faza

Faza 1

Qol Qrupları

QolMüdaxilə / müalicə
Experimental: Stage 1 Low dose
There are a total of 6 study visits within approximately a 6 month timespan. Investigators will evaluate the safety of a single administration of fresolimumab in adult patients with OI. Subjects will receive a single-dose of 1 mg/kg of fresolimumab (n=4). At each study visit, the participant may have the following testing done: Physical exam Vitals Blood draw for safety labs, pharmacokinetics, etc If the participant is female, she will have a pregnancy test EKG DXA Infusion of the study drug
Experimental: Stage 2 High dose
There are a total of 6 study visits within approximately a 6 month timespan. Investigators will evaluate the safety of a single administration of fresolimumab in adult patients with OI. Subjects will receive a single-dose of 4 mg/kg of fresolimumab (n=4). At each study visit, the participant may have the following testing done: Physical exam Vitals Blood draw for safety labs, pharmacokinetics, etc If the participant is female, she will have a pregnancy test EKG DXA Infusion of the study drug
Experimental: Stage 2 Repeat dose every 6 months
Fresolimumab will be administered every six months for a total treatment period of 12 months (n=4). The dose to be administered (1 or 4 mg/kg) will be chosen after completion of Stage 1. The primary Stage 2 endpoint will be safety measures assessed over 12 months. The secondary endpoints will be changes in markers of bone remodeling, bone mineral density, estimated strength. At each study visit, participants may have the following testing done: Physical exam Vitals Blood draw for safety labs, pharmacokinetics, etc If the participant is female, she will have a pregnancy test EKG DXA Infusion of the study drug Skeletal survey Peripheral quantitative CT (pQCT) of the forearm Quality of Life Surveys Pulmonary function test Walk test
Experimental: Stage 2 Repeat doses every 3 months
Fresolimumab will be administered every three months for a total treatment period of 12 months (n=4). The dose to be administered (1 or 4 mg/kg) will be chosen after completion of Stage 1. The primary Stage 2 endpoint will be safety measures assessed over 12 months. The secondary endpoints will be changes in markers of bone remodeling, bone mineral density, estimated strength. At each study visit, participants may have the following testing done: Physical exam Vitals Blood draw for safety labs, pharmacokinetics, etc If the participant is female, she will have a pregnancy test EKG DXA Infusion of the study drug Skeletal survey Peripheral quantitative CT (pQCT) of the forearm Quality of Life Surveys Pulmonary function test Walk test

Uyğunluq Kriteriyaları

Təhsil üçün uyğun yaşlar 18 Years Üçün 18 Years
Təhsilə Uyğun CinslərAll
Sağlam Könüllüləri qəbul edirBəli
Kriteriyalar

Inclusion Criteria:

1. Willing and able to provide signed informed consent.

2. Are 18 years or older

3. Have a diagnosis of moderate-to-severe OI based on various clinical features

4. Have genetic mutations that include glycine substitution in COL1A1 or COL1A2, or pathogenic variants in CRTAP, PPIB, or LEPRE1 (if genetic information is unavailable at screening, this may be assessed at screening visit on a clinical or research basis).

5. Females of child-bearing potential must have a negative urine pregnancy test, agree to and have the ability to use acceptable birth control method for entire duration of the study.

6. For Males enrolled in the study, partners must agree to use an acceptable form of birth control for the entire duration of the study.

Exclusion Criteria:

1. Fracture less than 3 months prior to the screening visit.

2. Rodding or instruments that prevents reliable bone mineral density (BMD) assessment.

3. Have a known unhealed fracture involving a long bone.

4. Do not meet laboratory safety requirements such as: Vitamin D < 15 ng/dL Serum albumin-corrected calcium levels below 8 mg/dL, Hemoglobin < 10 g/dL, Platelet count < 75,000mm3;, Prothrombin time/(PT/INR) international normalized ratio > 1.5 times Upper Limit of Normal (ULN), Clinical or laboratory abnormality of Grade III or higher as assessed by CTCAE v4.0 which in the view of investigator would compromise safety.

5. Have an EKG with QTc of > 450 ms

6. Have a known allergy to fresolimumab.

7. Have current clinically significant infection.

8. Have a personal history of basal cell carcinoma, squamous cell carcinoma or keratoacanthomas, a personal history of cancer, recent or remote.

9. Have evidence of untreated cavities or planned invasive dental work during the study period.

10. Have had organ transplantation.

11. Have known or suspected valvular heart disease.

12. Plan to have skeletal surgery in the study period.

13. Have had osteotomy 5 months prior to the screening visit.

14. Being treated with zoledronic acid or pamidronate less than 12 months of screening OR oral bisphosphonates less than 6 months of screening OR teriparatide less than one year of screening.

15. Being treated with systemic glucocorticoids

16. Have autoimmune diseases being treated with glucocorticoids or other biologic agents.

17. Enrolled in another clinical trial and receiving treatment with another investigational agent

18. Pregnant or planning to get pregnant during the study period.

19. Nursing mothers.

Nəticə

İlkin nəticə tədbirləri

1. Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 [6 months for single dose study and 12 months for repeat dose study]

Safety of single and repeat doses of fresolimumab will be assessed in adult patients with moderate to severe osteogenesis imperfecta

İkincili Nəticə Tədbirləri

1. Percentage change in type 1 procollagen, N-terminal or P1NP, Osteocalcin or Ocn, and C-terminal telopeptide or CTX [6 months in single dose study and 12 months in repeat dose study]

Markers of bone turnover in blood will be assessed

2. Percent change in the areal BMD at the lumbar spine and hip [6 months in single dose study and 12 months in repeat dose study]

Areal bone mineral density (aBMD) at the hip or the lumbar spine as measured by DXA Scan

3. Difference in score of numeric rating scale for pain [12 months]

The difference between baseline values and at month 12 will be assessed in the repeat dose study only

4. Change in ml in FEV1 [12 months]

The change in absolute volumes of FEV1 will be assessed between baseline and 12 months in the repeat dose study only

5. Change in ml in FVC [12 months]

The change in absolute volumes of FVC will be assessed between baseline and 12 months in the repeat dose study only

6. Percent change in volumetric bone mineral density at the radius [12 months]

pQCT of forearm will be performed to assess the change in volumetric bone mineral density between baseline and 12 months in the repeat dose study only.

7. Number of meters walked in 6 minutes [12 months]

Standard 6 minute walk test will be performed to assess the difference between baseline and 12 months in the repeat dose study only

Facebook səhifəmizə qoşulun

Elm tərəfindən dəstəklənən ən tam dərman bitkiləri bazası

  • 55 dildə işləyir
  • Elm tərəfindən dəstəklənən bitki mənşəli müalicələr
  • Təsvirə görə otların tanınması
  • İnteraktiv GPS xəritəsi - yerdəki otları etiketləyin (tezliklə)
  • Axtarışınızla əlaqəli elmi nəşrləri oxuyun
  • Təsirlərinə görə dərman bitkilərini axtarın
  • Maraqlarınızı təşkil edin və xəbər araşdırmaları, klinik sınaqlar və patentlər barədə məlumatlı olun

Bir simptom və ya bir xəstəlik yazın və kömək edə biləcək otlar haqqında oxuyun, bir ot yazın və istifadə olunan xəstəliklərə və simptomlara baxın.
* Bütün məlumatlar dərc olunmuş elmi araşdırmalara əsaslanır

Google Play badgeApp Store badge